臨床整形外科59巻5号

2024年05月発行

増大号特集 絶対！ 整形外科外傷学 2章　整形外来

Fix and Treat!—外傷病院から始める二次性骨折予防

著者： 脇貴洋¹

所属機関： ¹社会医療法人愛仁会明石医療センター整形外科

ページ範囲：P.559 - P.566

Point!

●脆弱性骨折は病的骨折であり，bone health optimization(骨の健康の最適化)が必要である．

●脆弱性骨折にはAO法に基づいた適切な骨接合と，術直後からの骨粗鬆症治療が重要である(fix and treat)．

●若手整形外科医が二次性骨折予防に関わりやすい環境の整備が指導医に求められる．

●骨粗鬆症治療が継続されるために，家族への骨粗鬆症治療の必要性の十分な説明と，初回再診外来のフォロー率向上が重要である．

参考文献

1) Werner M, Krause O, Macke C, et al. Orthogeriatric co-management for proximal femoral fractures. Can two additions make a big difference? BMC Musculoskelet Disord 2020;21(1):371. doi:10.1186/s12891-020-03392-1.0.

2) 骨粗鬆症の予防と治療ガイドライン作成委員会(日本骨粗鬆症学会，日本骨代謝学会，骨粗鬆症財団)(編)．骨粗鬆症の予防と治療ガイドライン　2015年版．東京：ライフサイエンス出版；2015．

3) Hagino H, Sawaguchi T, Endo N, et al. The risk of a second hip fracture in patients after their first hip fracture. Calcif Tissue Int 2012;90(1):14-21.

4) Anderson PA, Jeray KJ, Lane JM, et al. Bone health optimization:beyond own the bone:AOA critical issues. J Bone Joint Surg Am 2019;101(15):1413-9.

5) Leslie WD, Giangregorio LM, Yogendran M, et al. A population-based analysis of the post-fracture care gap 1996-2008:the situation is not improving. Osteoporos Int 2012;23(5):1623-9.

6) Balasubramanian A, Tosi LL, Lane JM, et al. Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009. J Bone Joint Surg Am 2014;96(7):e52. doi:10.2106/JBJS.L.01781.

7) Shibli-Rahhal A, Vaughan-Sarrazin MS, Richardson K, et al. Testing and treatment for osteoporosis following hip fracture in an integrated U.S. healthcare delivery system. Osteoporos Int 2011;22(12):2973-80.

8) Kung AW, Fan T, Xu L, et al. Factors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmenopausal women in Asian countries:a retrospective study. BMC Womens Health 2013;13:7. doi:10.1186/1472-6874-13-7.

9) Schuit SC, van der Klift M, Weel AE, et al. Fracture incidence and association with bone mineral density in elderly men and women:the Rotterdam Study. Bone 2004;34(1):195-202.

10) Bliuc D, Alarkawi D, Nguyen TV, et al. Risk of subsequent fractures and mortality in elderly women and men with fragility fractures with and without osteoporotic bone density:the Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 2015;30(4):637-46.

11) Cosman F, de Beur SJ, LeBoff MS, et al;National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int 2014;25(10):2359-81.

12) 脇　貴洋．Fix and treat—骨粗鬆症治療を開始するタイミング．整・災外2021；64(10)：1309-16．

13) Fujiwara S, Nakamura T, Orimo H, et al. Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 2008;19(4):429-35.

14) van Geel TACM, van Helden S, Geusens PP, et al. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis 2009;68(1):99-102.

15) Banefelt J, Åkesson KE, Spångéus A, et al. Risk of imminent fracture following a previous fracture in a Swedish database study. Osteoporos Int 2019;30(3):601-9.

16) Seto H, Ishimaru N, Ohnishi J, et al. Multidisciplinary team deprescribing intervention for polypharmacy in elderly orthopedic inpatients:a propensity score-matched analysis of a retrospective cohort study. Intern Med 2022;61(16):2417-26.

17) Saad FA. Novel insights into the complex architecture of osteoporosis molecular genetics. Ann N Y Acad Sci 2020;1462(1):37-52.

18) 富山市民病院高齢者大腿骨近位部骨折に対する多職種連携アプローチプロジェクトチーム．大腿骨近位部骨折チーム医療スターターガイド．東京：メジカルビュー社；2019．

19) Gopal S, Majumder S, Batchelor AG, et al. Fix and flap:the radical orthopaedic and plastic treatment of severe open fractures of the tibia. J Bone Joint Surg Br 2000;82(7):959-66.

20) Smith M, Giannoudis PV. Fragility fractures:a complex interaction of the health care system- the patient and the bone:can we do better? Injury 2017;48 Suppl 7:S1-3. doi:10.1016/j.injury.2017.08.029.

21) Reid IR, Billington EO. Drug therapy for osteoporosis in older adults. Lancet 2022;399(10329):1080-92.

22) Sakuma M, Endo N, Oinuma T, et al. Vitamin D and intact PTH status in patients with hip fracture. Osteoporos Int 2006;17(11):1608-14.

23) Okimoto N, Sakai A, Yoshioka T, et al. Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions:randomized, open-label, Japanese OZ study. J Bone Miner Metab 2020;38(2):230-9.

24) Ström S, Landfeldt E, Garellick G. Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA). Osteoporos Int 2015;26(1):315-25.

25) 顎骨壊死検討委員会．薬剤関連顎骨壊死の病態と管理：顎骨壊死検討委員会ポジションペーパー2023．https://www.jsoms.or.jp/medical/pdf/2023/0217_1.pdf(2023年12月4日アクセス)

26) Ferrari S, Langdahl B. Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone. Nat Rev Rheumatol 2023;19(5):307-17.

27) Kanis JA, Harvey NC, McCloskey E, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 2020;31(1):1-12. doi:10.1007/s00198-019-05176-3.

28) McClung MR, Grauer A, Boonen S, et al. Romosozumab in post-menopausal women with low bone mineral density. N Engl J Med 2014;370(5):412-20.

29) Lv F, Cai X, Yang W, et al:Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis:systematic review and meta-analysis. Bone 2020;130:115121. doi:10.1016/j.bone.2019.115121.

30) Sugimoto T, Shiraki M, Fukunaga M, et al. Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients:the TWICE study. Osteoporos Int 2019;30(11):2321-31.

31) Miller PD, Hattersley G, Riis BJ, et al;ACTIVE Study Investigators. Effect of abaloparatide vs placebo on new vertebral fractures in post-menopausal women with osteoporosis:a randomized clinical trial. JAMA 2016;316(7):722-33.

32) Soen S, Usuba K, Crawford B, et al. Family caregiver burden of patients with osteoporotic fracture in Japan. J Bone Miner Metab 2021;39(4):612-22.